HWG Holdings LP boosted its position in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 1,830.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,917 shares of the medical research company’s stock after acquiring an additional 13,196 shares during the quarter. PRA Health Sciences accounts for approximately 0.8% of HWG Holdings LP’s investment portfolio, making the stock its 29th biggest position. HWG Holdings LP’s holdings in PRA Health Sciences were worth $1,060,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of PRA Health Sciences by 12.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after buying an additional 160 shares during the period. Carroll Financial Associates Inc. boosted its stake in shares of PRA Health Sciences by 127.4% in the 3rd quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock valued at $112,000 after buying an additional 790 shares during the period. CAPROCK Group Inc. purchased a new position in shares of PRA Health Sciences in the 2nd quarter valued at about $208,000. Comerica Bank purchased a new position in shares of PRA Health Sciences in the 3rd quarter valued at about $214,000. Finally, Trustmark National Bank Trust Department purchased a new position in shares of PRA Health Sciences in the 2nd quarter valued at about $225,000. Institutional investors own 98.49% of the company’s stock.

Several equities analysts have recently issued reports on PRAH shares. Jefferies Group reiterated a “buy” rating and issued a $95.00 price objective on shares of PRA Health Sciences in a research note on Thursday, October 26th. Zacks Investment Research cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, August 29th. KeyCorp reiterated a “buy” rating and issued a $93.00 price objective (up previously from $86.00) on shares of PRA Health Sciences in a research note on Monday, October 30th. Credit Suisse Group reiterated an “outperform” rating and issued a $90.00 price objective (up previously from $84.00) on shares of PRA Health Sciences in a research note on Monday, October 16th. Finally, Robert W. Baird set a $94.00 price objective on PRA Health Sciences and gave the company a “buy” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $89.09.

In related news, Director Matthew P. Young sold 5,115 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.10% of the stock is owned by insiders.

Shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) opened at $81.00 on Wednesday. The firm has a market capitalization of $5,186.81, a P/E ratio of 30.09, a P/E/G ratio of 1.42 and a beta of 0.40. PRA Health Sciences, Inc. has a 52 week low of $52.76 and a 52 week high of $84.38. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.01 and a current ratio of 1.01.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.03. The firm had revenue of $494.55 million during the quarter, compared to analysts’ expectations of $477.89 million. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The firm’s revenue was up 23.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.64 earnings per share. analysts forecast that PRA Health Sciences, Inc. will post 3.2 EPS for the current year.

WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/06/pra-health-sciences-inc-prah-shares-bought-by-hwg-holdings-lp.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Stock Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related stocks with our FREE daily email newsletter.